(EDOC) Global X Telemedicine - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US37954Y2853 • Health
EDOC: Telemedicine, Digital Health, Healthcare
The Global X Telemedicine & Digital Health ETF (NASDAQ:EDOC) is designed to track the performance of companies poised to benefit from the growth and innovation in telemedicine and digital health. These companies operate in areas such as remote patient monitoring, telehealth platforms, and digital therapeutics. The fund is based on an index developed by Solactive AG, which identifies and includes exchange-listed firms aligned with these themes. The ETF employs a passive management strategy, aiming to replicate the performance of its underlying index rather than actively selecting securities. As a non-diversified fund, it may concentrate its holdings in a smaller number of issuers.
From a technical perspective, EDOC has shown recent price weakness, with its last price of $10.24 falling below its 20-day SMA of $11.00. However, the 50-day SMA of $10.63 suggests some stabilization in the intermediate term. The 200-day SMA of $9.75 indicates that the fund is still in an upward trend over the longer term. The Average True Range (ATR) of 0.26 reflects moderate volatility. Average daily trading volume over the past 20 days has been 16,482 shares, indicating limited liquidity.
Fundamentally, the ETF has assets under management (AUM) of $40.49 million, placing it in the smaller category of ETFs. This smaller size may result in higher sensitivity to market movements and potentially wider bid-ask spreads. Despite this, the fund provides targeted exposure to the telemedicine and digital health sector, which has seen increased adoption due to structural shifts in healthcare delivery.
Over the next three months, EDOC is likely to remain range-bound between $9.50 and $11.50, based on its current technical setup. The 20-day SMA crossing below the 50-day SMA suggests near-term weakness, but the 200-day SMA provides longer-term support. If the fund breaks above $11.00, it could test $11.50, while a breach below $9.75 may lead to a retest of $9.50. The ATR of 0.26 suggests that daily price fluctuations will remain moderate. On the fundamental side, continued growth in telehealth adoption and digital health innovation could drive upside, though the funds small AUM may limit its ability to capitalize on these trends without increased investor demand.
Additional Sources for EDOC ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EDOC ETF Overview
Market Cap in USD | 37m |
Category | Health |
TER | 0.68% |
IPO / Inception | 2020-07-29 |
EDOC ETF Ratings
Growth 5y | -31.1% |
Fundamental | - |
Dividend | 1.0% |
Rel. Strength Industry | -5.07 |
Analysts | - |
Fair Price Momentum | 8.13 USD |
Fair Price DCF | - |
EDOC Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 1.0% |
EDOC Growth Ratios
Growth Correlation 3m | 35.4% |
Growth Correlation 12m | 82.1% |
Growth Correlation 5y | -89.1% |
CAGR 5y | -9.90% |
CAGR/Max DD 5y | -0.15 |
Sharpe Ratio 12m | 1.00 |
Alpha | -6.42 |
Beta | 0.94 |
Volatility | 34.11% |
Current Volume | 409.3k |
Average Volume 20d | 15.5k |
As of March 14, 2025, the stock is trading at USD 9.61 with a total of 409,328 shares traded.
Over the past week, the price has changed by -6.15%, over one month by -14.96%, over three months by -6.24% and over the past year by +1.59%.
Probably not. Based on ValueRay Analyses, Global X Telemedicine (NASDAQ:EDOC) is currently (March 2025) not a good stock to buy. It has a ValueRay Growth Rating of -31.13 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EDOC as of March 2025 is 8.13. This means that EDOC is currently overvalued and has a potential downside of -15.4%.
Global X Telemedicine has no consensus analysts rating.
According to ValueRays Forecast Model, EDOC Global X Telemedicine will be worth about 9 in March 2026. The stock is currently trading at 9.61. This means that the stock has a potential downside of -5.93%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 9 | -5.9% |